Switching from reference infliximab to CT-P13 in patients with inflammatory bowel disease: results of a multicenter study after 12 months

Switching from reference infliximab to CT-P13 in patients with inflammatory bowel disease: results of a multicenter study after 12 months

ABSTRACT Background and aims: infliximab has changed the natural history of inflammatory bowel disease (IBD). The advent of biosimilar treatments such as CT-P13 will hopefully improve the availability of biological therapies. Data with regard to drug switching are currently limited. The objective o...

Full description

Bibliographic Details
Main Authors: Maria-Fernanda Guerra-Veloz, Juan-María Vázquez-Morón, María Belvis-Jiménez, Héctor Pallarés-Manrique, Teresa Valdés-Delgado, Luisa Castro-Laria, Belén Maldonado-Pérez, Antonio Benítez-Roldán, Raúl Perea-Amarillo, Vicente Merino, Ángel Caunedo-Álvarez, Ángel Vilches-Arenas, Federico Argüelles-Arias
Format: Article
Language:English
Published: Aran Ediciones 2018-09-01
Series:Revista Espanola de Enfermedades Digestivas
Subjects:
Crohn's disease
Ulcerative colitis
Inflammatory bowel disease
Biosimilar agent
CT-P13
Infliximab
Online Access:http://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S1130-01082018000900006&tlng=en

Internet

http://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S1130-01082018000900006&tlng=en

Similar Items